Phase I, Single Center, Trial to Asses Safety and Tolerability of the Intrathecal Infusion of Ex-vivo Expanded Bone-marrow Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury

Trial Profile

Phase I, Single Center, Trial to Asses Safety and Tolerability of the Intrathecal Infusion of Ex-vivo Expanded Bone-marrow Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury

Suspended
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Autologous stem cell therapy (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions
  • Sponsors TCA Cellular Therapy
  • Most Recent Events

    • 08 May 2014 Planned End Date changed from 1 Dec 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 08 May 2014 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
    • 07 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top